

Intensive Care and Organ Support Related Mortality in Patients With COVID-19: A Systematic Review and Meta-Analysis

OBJECTIVES: To perform a systematic review and meta-analysis to generate estimates of mortality in patients with COVID-19 that required hospitalization, ICU admission, and organ support.

DATA SOURCES: A systematic search of PubMed, Embase, and the Cochrane databases was conducted up to December 31, 2021.

STUDY SELECTION: Previously peer-reviewed observational studies that reported ICU, mechanical ventilation (MV), renal replacement therapy (RRT) or extracorporeal membrane oxygenation (ECMO)-related mortality among greater than or equal to 100 individual patients.

DATA EXTRACTION: Random-effects meta-analysis was used to generate pooled estimates of case fatality rates (CFRs) for in-hospital, ICU, MV, RRT, and ECMO-related mortality. ICU-related mortality was additionally analyzed by the study country of origin. Sensitivity analyses of CFR were assessed based on completeness of follow-up data, by year, and when only studies judged to be of high quality were included.

DATA SYNTHESIS: One hundred fifty-seven studies evaluating 948,309 patients were included. The CFR for in-hospital mortality, ICU mortality, MV, RRT, and ECMO were 25.9% (95% CI: 24.0–27.8%), 37.3% (95% CI: 34.6–40.1%), 51.6% (95% CI: 46.1–57.0%), 66.1% (95% CI: 59.7–72.2%), and 58.0% (95% CI: 46.9–68.9%), respectively. MV (52.7%, 95% CI: 47.5–58.0% vs 31.3%, 95% CI: 16.1–48.9%; $p = 0.023$) and RRT-related mortality (66.7%, 95% CI: 60.1–73.0% vs 50.3%, 95% CI: 42.4–58.2%; $p = 0.003$) decreased from 2020 to 2021.

CONCLUSIONS: We present updated estimates of CFR for patients hospitalized and requiring intensive care for the management of COVID-19. Although mortality remain high and varies considerably worldwide, we found the CFR in patients supported with MV significantly improved since 2020.

KEY WORDS: COVID-19; mechanical ventilation; pneumonia; respiratory distress syndrome; respiratory insufficiency; viral

Over 6.5 million deaths related to COVID-19 have been reported worldwide since December 2019. The unprecedented spread of the virus and the high proportion of severely ill patients requiring intensive care and organ support have strained hospital systems around the world (1). The heavy human toll created widespread disarray and misinformation among communities. The medical community was faced with two challenges: overcome saturated capacity and strained resources on the one hand and provide accurate information to patients and families regarding the morbidity and prognosis of the disease on the other. For ICU providers, patients, and their families, there was an immediate need to understand what the mortality was for patients that

Abhimanyu Chandel, MD¹

Sahar Leazer, MD^{2,3}

Karl C. Alcover, PhD²

Josiah Farley, BS²

Joshua Berk, BA²

Christopher Jayne, BS²

Ryan Mcnutt, BS²

Meredith Olsen, MD¹

Rhonda Allard, MLIS²

Jiahong Yang, BS²

Caitlyn Johnson, BS²

Ananya Tripathi, BS²

Maria Rechten, MD¹

Mathew Leon, MMSc²

Mathias Williams, MD¹

Phorum Sheth, MS²

Kyle Messer, DO¹

Kevin K. Chung, MD²

Jacob Collen, MD^{1,2}

Copyright © 2023 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of the Society of Critical Care Medicine. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

DOI: 10.1097/CCE.0000000000000876



KEY POINTS

Question: What is the overall mortality in patients that required hospitalization, ICU admission, and organ support related to COVID-19?

Findings: In this meta-analysis, including nearly 1 million patients with COVID-19, the case fatality rate for in-hospital mortality, ICU mortality, mechanical ventilation, renal replacement therapy, and extracorporeal membrane oxygenation were 25.9%, 37.3%, 51.6%, 66.1%, and 58.0%, respectively. Mechanical ventilation mortality has decreased significantly since the start of the pandemic.

Meaning: These updated and robust estimates of case fatality rates for critically ill patients with COVID-19 can be applied to guide patient counseling and further clinical research regarding the management of this disease.

were admitted to the ICU and required organ support modalities, in particular, mechanical ventilation (MV). Strikingly in modern medicine, we were faced with the reality of potentially needing to ration ICU care. If the mortality for a patient undergoing intubation and MV was upwards of 75%, it would be reasonable to consider not providing a precious, limited resource to that patient, and instead allot it to a younger patient with a better overall prognosis. Therefore, mortality estimates in this pandemic had an immediacy to direct patient care.

Clinical outcomes in a pandemic are affected by variables beyond pathogenicity, patient risk and illness severity. Patients treated in the first wave of a pandemic may have worse outcomes due to supply-demand mismatch for intensive care (2). The current pandemic has exposed limitations of critical care disaster management at large tertiary care centers in first-world nations (3). Comparing critical care outcomes between illnesses occurring in usual care settings and pandemics or other disasters may fail to account for these factors (4).

Mortality estimates among patients with COVID-19 that require intensive care, MV, and organ support have varied substantially over the course of the ongoing pandemic (5). Accurate estimation of these mortality rates have been challenged by considerations

including the rapid emergence of this new pathogen, surges in cases resulting in breakdowns in care delivery models, staffing shortages, resource limitations, and the struggle to identify optimal ICU management of this new viral pathogen (5). Further, many prior estimates of mortality in the ICU were based on emerging data that had yet to undergo peer review and included patients with variable and incomplete follow-up periods (6, 7). Given these constraints, outcome estimates often were made including patients still receiving ICU support at the time of data reporting.

To ensure accurate information to facilitate expectation management, resource allocation, and patient counseling, it is critical to update prior estimates of ICU-related outcomes. We conducted a systematic review and meta-analysis to generate estimates of mortality in patients with COVID-19 that required hospitalization and ICU care. We further examined mortality based on specific organ support required, geographic region, and based on the availability of complete follow-up data.

MATERIALS AND METHODS

Our systematic review and meta-analysis were conducted in accordance with the recommendations established by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. This review was not prospectively registered.

Eligibility Criteria

Previously peer-reviewed and published English language observational studies that met the population, intervention, comparison, outcome, and study design criteria were eligible for inclusion in this systematic review. Studies were included if they reported ICU, MV, renal replacement therapy (RRT), or extracorporeal membrane oxygenation (ECMO)-related mortality of patients with COVID-19 and were published between December 1, 2019, and December 31, 2021. To maximize the quality of the analyzed data, we excluded reports of less than 100 patients, articles not presenting original data, studies with pediatric populations, and preprints. The search was conducted through February 2022 by a professional medical librarian (R.A.). We carried out electronic searches of PubMed, Embase, and the Cochrane databases using the following search terms: COVID-19, novel coronavirus 2019 and MV,

intubation, pneumonia, ICU, critical care, critically ill patients, severely ill patients, clinical characteristics, mortality, and outcomes.

Study Selection

After search results were obtained, two of the authors (S.L., J.C.) independently screened and selected articles by title and abstract and cross-matched selections with the other. Full-text articles were then reviewed by the same method. The following study authors (A.C., S.L., J.F., J.B., C.J., R.M., M.O., J.Y., A.T., M.R., M.L., M.W., P.S., K.M.) extracted data in pairs from each article and resolved disagreement by consensus. The data extracted included the following variables: date of publication, authors, geographic region, study design, country of origin, age, gender, number of patients admitted to the ICU, number of patients supported with MV, RRT, and ECMO, ICU mortality, and mortality associated with organ support (MV, RRT, and ECMO). Complete study follow-up was defined as studies where all included patients had either recovered and been discharged or had died. In these instances, reported outcomes did not include patients where final disposition remained uncertain at the time of data reporting.

Quality Assessment

All included studies were retrospective cohort studies. The quality of the included studies was assessed independently by two researchers based on the Newcastle-Ottawa Scale (NOS) (8). Using this tool, each study was judged on eight items, categorized into three groups: the selection of the study groups; the comparability of the groups; and the ascertainment of either the exposure or outcome of interest for case-control or cohort studies, respectively. Stars are awarded such that the highest quality studies are awarded up to eight stars.

Statistical Analysis

Each outcome variable was analyzed separately. For each outcome, a case fatality rate (CFR) was estimated by the meta-analytic summary estimate obtained from conducting meta-analysis of study-specific proportions of death. In each study, CFR was calculated by taking the number of deaths and dividing it by the

total number of confirmed cases (i.e., hospital patients with confirmed cases of COVID-19). CFR includes only the confirmed cases (denominator) as opposed to the total number in the at-risk population, which is the denominator in calculating mortality rate (not analyzed).

The meta-analysis employed a random-effects model with DerSimonian and Laird estimator and estimated heterogeneity using the inverse-variance fixed-effect model. For studies with the proportions equal to (or close to) 0 or 1, the variance estimates were stabilized using the Freeman-Tukey double arcsine transformation of the data. The pooled estimate of the rate was then back transformed and presented, along with their Wald 95% CI estimated using the Score method. Heterogeneity between studies was estimated using the I^2 statistic and its p value. In this study, we used the pooled estimates obtained from the meta-analysis to report the fatality rates, which are often different from the rates obtained by manually combining all the number of deaths and cases from individual studies. Publication bias was assessed by examining visually the funnel plots and performing Egger tests. We also explored subgroup variations based on the analysis of complete cases only, stratified by date of last admission (ending on or before December 31, 2020), and when only studies rated as “Good” quality by NOS were included. Finally, as an exploratory analysis of how outcome varies based on geographic region, outcomes were stratified by primary country of data collection. All statistical analyses were conducted in Stata statistical software Version 17 (StataCorp LLC, College Station, TX). The meta-analysis of proportions used the *metaprop* command in Stata.

RESULTS

Study Selection and Characteristics

The complete literature-search process is displayed in **Figure 1**. A total of 11,442 abstracts were retrieved. After screening by abstract and title, 571 articles were selected for full-text assessment. In total, 157 studies evaluating 948,309 patients were included in the meta-analysis (9–159). The characteristics of all the included studies are shown in **Table S1** (<http://links.lww.com/CCX/B152>). Of the included patients, 54.2% were male and the median age of the cohorts ranged from 34 to 73 years old.




Figure 1. Preferred Reporting Items for Systematic Reviews flowchart of included and excluded studies.

In-Hospital Case Fatality Rate

A total of 157 studies were included that reported death in patients admitted to the hospital with COVID-19. The total number of in-hospital deaths observed was 290,996 resulting in an overall estimated in-hospital CFR of 25.9% (95% CI: 24.0–27.8%; $I^2 = 99.6\%$) (Table 1). The in-hospital CFR was significantly higher ($p = 0.018$) in studies with complete follow-up (27.9%, 95% CI: 24.4–31.6%; $I^2 = 99.6\%$) compared with studies without follow-up data (22.8%, 95% CI: 20.5–25.2%; $I^2 = 99.4\%$) (Table S2, <http://links.lww.com/CCX/B152>). Estimated in-hospital CFR was numerically higher when compared based on year of the pandemic

TABLE 1.
Overall Results of the Meta-Analysis

Hospital and Organ Support Related Mortality	Meta-Analysis Summary	
	Rate (%)	95% CI (%)
In-hospital	25.9	24.0–27.8
ICU	37.3	34.6–40.1
Mechanical ventilation	51.6	46.1–57.0
Renal replacement therapy	66.1	59.7–72.2
Extracorporeal membrane oxygenation	58.0	46.9–68.9

(2020 vs 2021; $p = 0.102$) (25.3%, 95% CI: 23.4–27.3%; $I^2 = 99.6\%$ vs 31.4%, 95% CI: 24.5–38.6%; $I^2 = 99.6\%$) (Table S3, <http://links.lww.com/CCX/B152>).

ICU Case Fatality Rate

Of the included studies, 155 reported deaths in the ICU (Fig. S1, <http://links.lww.com/CCX/B152>). The total number of deaths in the ICU was 175,115 with an overall estimated ICU CFR of 37.3% (95% CI: 34.6–40.1%; $I^2 = 99.6\%$) (Table 1). The ICU CFR in studies with complete follow-up (41.2%, 95% CI: 37.2–45.2%; $I^2 = 99.3\%$) was higher compared with studies that reported estimates including patients with incomplete follow-up data (32.3%, 95% CI: 27.3–37.2%) and this difference was statistically significant ($p = 0.006$) (Fig. 2A). Estimated ICU CFR was similar when compared based on year of the pandemic (2020 vs 2021) (37.4%, 95% CI: 34.3–40.5% vs 36.6%, 95% CI: 29.8–43.7%; $p = 0.839$) (Fig. 2B) and when estimates were made restricting included studies to those rated as having good overall quality (39.5%, 95% CI: 36.4–42.5%) (Table S4, <http://links.lww.com/CCX/B152>).

MV Case Fatality Rate

A total of 118,862 deaths in patients that received MV were reported in 77 studies (Fig. S2, <http://links.lww.com/CCX/B152>). The overall MV CFR across all studies was 51.6% (95% CI: 46.1–57.0%; $I^2 = 99.7\%$). The MV CFR in studies with complete follow-up (56.8%, 95% CI: 49.8–63.8%; $I^2 = 99.6\%$) was higher compared with studies including patients with incomplete follow-up data (44.0%, 95% CI: 31.6–56.7%; $I^2 = 99.7\%$), although this difference was not statistically significant ($p = 0.082$). Interestingly, MV CFR significantly decreased ($p = 0.023$) from 2020 to 2021 (52.7%, 95% CI: 47.5–58.0%; $I^2 = 99.6\%$ vs 31.3%, 95% CI: 16.1–48.9%; $I^2 = 99.5\%$). Estimated MV CFR remained similar when analysis was restricted to only good quality studies (54.1%, 95% CI: 47.6–60.5%; $I^2 = 99.7\%$).

RRT Case Fatality Rate

A total of 1,286 deaths in patients that received RRT across the studies (of 2,047 patients that received RRT) and the overall CFR of RRT was 66.1% (95% CI: 59.7–72.2%; $I^2 = 84.3\%$). The RRT CFR in studies with complete follow-up (69.8%, 95% CI: 61.8–77.2%; $I^2 =$




Figure 2. Intensive care unit case fatality rate. **A**, Case fatality rates stratified by complete versus incomplete follow-up data. **B**, Case fatality rates stratified by year of the end of study enrollment. ECMO = extracorporeal membrane oxygenation, MV = mechanical ventilation, RRT = renal replacement therapy.

83.7%) was higher compared with studies including patients with incomplete follow-up data (59.2%, 95% CI: 47.8–70.1%; $I^2 = 82.5\%$), although this difference was not statistically significant ($p = 0.087$). Like the MV CFR, the RRT CFR significantly decreased ($p = 0.003$) from 2020 to 2021 (66.7%, 95% CI: 60.1–73.0%; $I^2 = 83.9\%$ vs 50.3%, 95% CI: 42.4–58.2%; $I^2 =$ not available). Estimated RRT CFR remained similar when analysis was restricted to only good quality studies (65.4%, 95% CI: 58.2–72.3%; $I^2 = 65.4\%$).

ECMO Case Fatality Rate

A total of 275 ECMO-related deaths were reported across the studies (of 482 patients that were supported with ECMO). The overall ECMO CFR across

these studies was 58.0% (95% CI: 46.9–68.9%; $I^2 = 71.2\%$). The ECMO CFR in studies with complete follow-up (55.9%, 95% CI: 42.7–68.8%; $I^2 = 66.3\%$) was similar compared with studies including patients with incomplete follow-up data (59.6%, 95% CI: 33.5–83.7%; $I^2 = 76.5\%$). Insufficient data were available to compare how outcomes differed from 2020 to 2021.

ICU Case Fatality Rate by Country

Studies included represented data reported from a total of 42 countries (Table S5, <http://links.lww.com/CCX/B152>). Most studies were from the United States ($n = 22$), the United Kingdom ($n = 11$), and China ($n = 16$). The ICU CFR varied widely across




Figure 3. ICU case fatality rate for countries with available data encompassing more than 5,000 total patients.

the included countries ranging from as low as less than 15% (Australia, Iceland, Qatar, and the United Arab Emirates) to as high as 84% (Nepal). ICU CFR for countries with available data encompassing more than 5,000 total patients is included in **Figure 3**. Notably, among these countries, ICU CFR was lowest in France (24.2%; $I^2 = 93.8\%$) and Sweden (20%; $I^2 = 90.7\%$) while substantially higher in the United States (47.0%; $I^2 = 95.0\%$) and Mexico (60.2%; $I^2 = 94.4\%$).

Risk of Bias Assessment

Risk of bias was assessed through funnel plots of the estimates versus the estimate precisions and are displayed in **Figures S3–S7** (<http://links.lww.com/CCX/B152>). The Eggers test demonstrated evidence suggestive of “small-study effects” ($p < 0.05$) for the outcomes of ICU and MV-related mortality. Additionally, visual inspection of the funnel plots for all in-hospital, ICU, and MV revealed asymmetry, which suggests publication bias or other relevant bias may be present.

DISCUSSION

In our meta-analysis and systematic review including nearly 1 million patients with COVID-19, we found an overall ICU CFR of 37.3% and a MV CFR of 51.6%. Among studies including complete follow-up data, the ICU CFR was 41.2% and the MV CFR was 56.8%. The overall ICU CFR of patients with COVID-19

remained unchanged over the first 2 years of the pandemic; however, the overall CFR for patients that require MV decreased substantially from 2020 to 2021 (52.7–31.3%). The presented results are valuable given the size, temporal, and geographic diversity of the collated patients. Furthermore, the results are likely to be reliable given the inclusion of only studies reporting results from at least 100 patients and the inclusion of a sensitivity analysis confirming results are similar when only the highest quality studies were analyzed. Analysis of studies that report completed follow-up also strengthens the accuracy of our estimates. Our study provides the largest systematic analysis of COVID-19 ICU outcomes to date, with more reliable estimates of mortality rates that can assist clinicians who counsel patients about potential outcomes in the ICU while also demonstrating that these outcomes have improved over the course of the pandemic.

Mortality among patients with COVID-19 treated in the ICU and with MV has been estimated in smaller meta-analyses performed earlier in the pandemic. In a systematic review of studies published before May 1, 2020, including over 12,000 patients from 28 studies (including 11 studies that had not undergone peer-review), ICU mortality was estimated at 28.3%, while mortality of patients requiring MV was estimated at 43% (7). Relatedly, four other systematic reviews of studies published prior to September 30, 2020, found the ICU CFR to range between 34% and 42% (160–163). Similarly, a separate systematic review incorporating only data from 2020 (including 14 studies that were not

peer-reviewed) estimated the MV CFR to be 45% (164). Whereas other reviews from 2020 found MV CFR to range considerably from 43% to 83% (7, 163, 165). A notable limitation of estimates of CFR related to the ongoing COVID-19 pandemic has been the rapid emergence of data and the related publication of data from cohorts where a sizable percentage of patients studied remained hospitalized related to COVID-19 and significant clinical, methodological, and statistical heterogeneity exists. As such, many of these prior systematic reviews provided estimates to consider best and worse-case scenarios estimates for CFR incorporating this incomplete data (7, 161, 164). These sensitivity analyses resulted in even further variability in CFR estimates and necessitated updated systematic review once additional data in patients with complete clinical follow-up have become available (162).

Our group previously reported a systematic review presenting data related to critical care outcomes in patients with COVID-19 (166). This review was limited by its inclusion of low-quality small sample studies and the restriction to studies published before the start of 2021. To ensure the availability of high-quality epidemiologic data that incorporates all published data to date, we chose to update this prior work. Compared with this prior systematic review, our current study incorporated data from nearly 15 times as many patients, allowing for more precise and robust estimates of CFR across outcomes. These updated estimates allow for more appropriate patient-physician counseling, resource management, and clinical trial planning.

In this current analysis, compared with 2020, patients critically ill with COVID-19 supported with organ support in 2021 had substantially lower observed CFRs related to MV and RRT. Interestingly, the ICU CFR did not change from 2020 to 2021. This discrepancy is challenging to reconcile and raises the possibility that changes in care strategies, such as more frequent and prolonged utilization of noninvasive respiratory support, application of noninvasive ventilation outside of ICU settings, and reluctance or shortages of resources to provide RRT may have resulted in the observed changes in organ-specific CFRs (167, 168).

The notion that resource constraints and case volume can have unpredictable effects on mortality has been discussed by other investigators. Kadri et al (169) demonstrated an increase in mortality linked to surges in cases and overall hospital loads between August 2020

and October 2020. Another study by Dale et al (2) found that there was a significant decrease in survival to hospital discharge in patients with COVID-19 when a higher percentage of the hospital census was occupied by patients with COVID-19. Outside of resource-limited environments and the current pandemic, the medical community has generally noted that concentrated caseloads lead to better outcomes due to the increased relative expertise of the treatment teams (170). However, during the COVID-19 pandemic, we were confronted with extreme limitations in staffing, standard critical care treatment modalities, hospital beds, and even personal protective equipment. The magnitude of these limitations and the climate that accompanied these challenges likely amplified the impact of resource constraints. Unfortunately, the studies we reviewed are inadequate for evaluating the impact of confounding factors such as nurse-to-patient ratios in the ICU, relative or absolute equipment shortages, physician-to-patient ratios, or numerous other factors that may lead to poorer patient outcomes. It is reasonable to infer that those facilities which experienced higher caseloads were at greater risk of becoming overwhelmed compared with facilities with smaller or more select caseloads. Relatedly, we observed a wide variation in CFR based on country of origin of the included studies. Likely, this observation reflects a combination of factors including reporting bias, medical infrastructure, severity and burden of viral outbreaks, and the influence, rapid uptake, and utilization of effective COVID-19 treatments. Although based on our current data, we can only speculate as to the cause of these discrepancies, the observed wide differences in CFR worldwide emphasizes the need for further study of these outcome inequities.

It is also worth noting that some studies found no difference in mortality among patients with COVID-19 during surge months or based on resource availability (171). However, it is possible that hospitals worldwide experienced a surge of patients with COVID-19 during different time frames based on spread of the culprit virus, and this variation in timing was a confounding factor in applied analyses. For example, one study found that there was no difference in mortality among different ICUs averaged over comparable time frames, but when the data was analyzed on individual ICU outcomes, it was apparent that individual ICUs did have substantially higher mortality during surge months (3). Clarifying the impact of resource

constraints would require studies that have predefined endpoints looking at resource-related variables linked to outcomes.

Our review has several limitations that should be acknowledged. First, although our analysis encompasses the largest cohort of critically ill patients with COVID-19 to date, it is limited by the availability and heterogeneity of published data. The presented findings correspond to an update of existing data. Although this limits the novelty of the findings, it is valuable to continue to update the expected clinical outcomes of patients with COVID-19 as the pandemic continues to evolve. Several geographic regions are underrepresented by the currently available data, and it is critical that such data be gathered to improve public health understanding of the impact of the COVID-19 pandemic. As such, our results may not be generalizable to these underrepresented regions. Further, there is substantial heterogeneity regarding standardized data reporting, definitions of intensive care, and resource availability around the world. Relatedly, assessment of the risk of bias related to the publication demonstrated the potential for small-study effects and publication bias, which may impact the precision of our results. We choose to analyze CFR as a measure of the severity of disease outbreak as this index allows for the estimation of rate of death among confirmed cases which is essential to characterize a disease outbreak. Although suited for this goal, CFR has the potential to overestimate the outcome rate in regions where COVID-19 testing may be limited. Finally, although outcomes of patients supported with MV or RRT appear to have improved over the course of the COVID-19 pandemic, the cause of this observation could not be identified and likely reflects the convergence of multiple factors potentially including available treatments and immunizations, which may have reduced the severity of illness over the course of the pandemic. Due to the potential for substantial bias resulting from the retrospective analysis of these factors, which would make interpretation of these data challenging, the impact of these factors was not examined in this current work. Likewise, the emergence of viral variants has likely influenced ICU outcomes. However, as these variants have impacted geographic regions at varying paces, their impact on ICU and organ support outcomes could also not be assessed directly in this review.

In conclusion, in this large meta-analysis of studies reporting data representing at least 100 patients with COVID-19, we found the ICU and MV CFR to be 37.3% and 51.6%, respectively. Although the CFR related to MV appears to have improved considerably since 2020, ICU mortality remains high. The mortality is in line with the worst outcomes of other respiratory pandemics in recent history, only on a greater scale. Even with advances in care over the course of the pandemic, outcome improvements have been modest for those patients that are critically ill or require MV. These data are valuable to guide expectation management, resource allocation, and patient counseling.

1 Department of Pulmonary and Critical Care Medicine, Walter Reed National Medical Center, Bethesda, MD.

2 Department of Medicine, Uniformed Services University of Health Sciences, Bethesda, MD.

3 The Metis Foundation, San Antonio, TX.

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's website (<http://journals.lww.com/ccejjournal>).

The authors have disclosed that they do not have any potential conflicts of interest.

For information regarding this article, E-mail: Abhimanyu.chandel.mil@health.mil

All data used in the analysis is available upon reasonable request.

The views expressed in this article are those of the author and do not necessarily reflect the official policy of the Uniformed Services University of Health Sciences, the Department of Defense, or the U.S. Government.

REFERENCES

- French G, Hulse M, Nguyen D, et al: Impact of hospital strain on excess deaths during the COVID-19 pandemic-United States, July 2020-July 2021. *Am J Transplant* 2022; 22:654-657
- Dale CR, Starcher RW, Chang SC, et al: Surge effects and survival to hospital discharge in critical care patients with COVID-19 during the early pandemic: A cohort study. *Crit Care* 2021; 25:70
- Keene AB, Admon AJ, Brenner SK, et al; STOP-COVID Investigators: Association of surge conditions with mortality among critically ill patients with COVID-19. *J Intensive Care Med* 2022; 37:500-509
- Salluh JIF, Kurtz P, Bastos LSL, et al: The resilient intensive care unit. *Ann Intensive Care* 2022; 12:37
- Auld SC, Harrington KRV, Adelman MW, et al; Emory COVID-19 Quality and Clinical Research Collaborative: Trends in ICU mortality from coronavirus disease 2019: A tale of three surges. *Crit Care Med* 2022; 50:245-255

6. Richardson S, Hirsch JS, Narasimhan M, et al; the Northwell COVID-19 Research Consortium: Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area. *JAMA* 2020; 323:2052–2059
7. Chang R, Elhousseiny KM, Yeh YC, et al: COVID-19 ICU and mechanical ventilation patient characteristics and outcomes—a systematic review and meta-analysis. *PLoS One* 2021; 16:e0246318
8. Wells GA, Shea B, O'Connell D, et al: The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses. 2014. Available at: https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed May 25, 2022
9. Cao J, Tu WJ, Cheng W, et al: Clinical features and short-term outcomes of 102 patients with coronavirus disease 2019 in Wuhan, China. *Clin Infect Dis* 2020; 71:748–755
10. Yang L, Liu J, Zhang R, et al: Epidemiological and clinical features of 200 hospitalized patients with corona virus disease 2019 outside Wuhan, China: A descriptive study. *J Clin Virol* 2020; 129:104475
11. Huang R, Zhu L, Xue L, et al: Clinical findings of patients with coronavirus disease 2019 in Jiangsu province, China: A retrospective, multi-center study. *PLoS Negl Trop Dis* 2020; 14:e0008280
12. Wang Y, Liao B, Guo Y, et al: Clinical characteristics of patients infected with the novel 2019 coronavirus (SARS-Cov-2) in Guangzhou, China. *Open Forum Infect Dis* 2020; 7:ofaa187
13. Zhang G, Hu C, Luo L, et al: Clinical features and short-term outcomes of 221 patients with COVID-19 in Wuhan, China. *J Clin Virol* 2020; 127:104364
14. Feng Y, Ling Y, Bai T, et al: COVID-19 with different severities: A multicenter study of clinical features. *Am J Respir Crit Care Med* 2020; 201:1380–1388
15. Lei C, Lin W, Deng X, et al: Factors associated with clinical outcomes in patients with coronavirus disease 2019 in Guangzhou, China. *J Clin Virol* 2020; 133:104661
16. Feng X, Li P, Ma L, et al: Clinical characteristics and short-term outcomes of severe patients with COVID-19 in Wuhan, China. *Front Med (Lausanne)* 2020; 7:491
17. Wang Y, Lu X, Li Y, et al: Clinical course and outcomes of 344 intensive care patients with COVID-19. *Am J Respir Crit Care Med* 2020; 201:1430–1434
18. Guo F, Xie J, Wu W, et al: Clinical characteristics and outcomes of critically ill patients with coronavirus disease 2019 with hypotension in China: A retrospective cohort study. *Ann Palliat Med* 2021; 10:8536–8546
19. Liu J, Zhang S, Wu Z, et al: Clinical outcomes of COVID-19 in Wuhan, China: A large cohort study. *Ann Intensive Care* 2020; 10:99
20. Chen Y, Linli Z, Lei Y, et al: Risk factors for mortality in critically ill patients with COVID-19 in Huanggang, China: A single-center multivariate pattern analysis. *J Med Virol* 2021; 93:2046–2055
21. Richards-Belle A, Orzechowska I, Doidge J, et al: Critical care outcomes, for the first 200 patients with confirmed COVID-19, in England, Wales and Northern Ireland: A report from the ICNARC case mix programme. *J Intensive Care Soc* 2021; 22:270–279
22. Berenguer J, Ryan P, Rodríguez-Baño J, et al: Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain. *Clin Microbiol Infect* 2020; 26:1525–1536
23. Grasselli G, Zangrillo A, Zanella A, et al; COVID-19 Lombardy ICU Network: Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. *JAMA* 2020; 323:1574–1581
24. Oliveira E, Parikh A, Lopez-Ruiz A, et al: ICU outcomes and survival in patients with severe COVID-19 in the largest health care system in central Florida. *PLoS One* 2021; 16:e0249038
25. Shahriarirad R, Khodamoradi Z, Erfani A, et al: Epidemiological and clinical features of 2019 novel coronavirus diseases (COVID-19) in the South of Iran. *BMC Infect Dis* 2020; 20:427
26. Suleyman G, Fadel RA, Malette KM, et al: Clinical characteristics and morbidity associated with coronavirus disease 2019 in a series of patients in Metropolitan Detroit. *JAMA Netw Open* 2020; 3:e2012270
27. Kaeuffer C, Le Hyaric C, Fabacher T, et al: Clinical characteristics and risk factors associated with severe COVID-19: Prospective analysis of 1,045 hospitalised cases in North-Eastern France, March 2020. *Euro Surveill* 2020; 25:2000895
28. Alharthy A, Aletreby W, Faqih F, et al: Clinical characteristics and predictors of 28-day mortality in 352 critically ill patients with COVID-19: A retrospective study. *J Epidemiol Glob Health* 2021; 11:98–104
29. Fleuren LM, Tonutti M, de Bruin DP, et al; Dutch ICU Data Sharing Against COVID-19 Collaborators: Risk factors for adverse outcomes during mechanical ventilation of 1152 COVID-19 patients: A multicenter machine learning study with highly granular data from the Dutch Data Warehouse. *Intensive Care Med* 2021; 9:32
30. Khan A, Althunayyan S, Alsofayan Y, et al: Risk factors associated with worse outcomes in COVID-19: A retrospective study in Saudi Arabia. *East Mediterr Health J* 2020; 26:1371–1380
31. Martinot M, Eyriey M, Gravier S, et al; Centre Alsace COVID-19 Study Group: Predictors of mortality, ICU hospitalization, and extrapulmonary complications in COVID-19 patients. *Infect Dis Now* 2021; 51:518–525
32. Bidari A, Hassanzadeh M, Naderkhani M, et al: Predictors of critical COVID-19 in an Iranian population: Age and disabilities play a special role. *Med J Islam Repub Iran* 2021; 35:94
33. Botta M, Tsonas AM, Pillay J, et al; PRoVENT-COVID Collaborative Group: Ventilation management and clinical outcomes in invasively ventilated patients with COVID-19 (PRoVENT-COVID): A national, multicentre, observational cohort study. *Lancet Respir Med* 2021; 9:139–148
34. Cummings MJ, Baldwin MR, Abrams D, et al: Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: A prospective cohort study. *Lancet* 2020; 395:1763–1770
35. Zhou S, Yang Y, Zhang X, et al: Clinical course of 195 critically ill COVID-19 patients: A retrospective multicenter study. *Shock* 2020; 54:644–651
36. Argenziano MG, Bruce SL, Slater CL, et al: Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: Retrospective case series. *BMJ* 2020; 369:m1996

37. Kim EJ, Lee YH, Park JS, et al: Clinical features and prognostic factors of critically ill patients with COVID-19 in Daegu, South Korea: A multi-center retrospective study. *Medicine (Baltim)* 2021; 100:e24437
38. Mukherjee V, Toth AT, Fenianos M, et al: Clinical outcomes in critically ill coronavirus disease 2019 patients: A unique New York City public hospital experience. *Crit Care Explor* 2020; 2:e0188
39. Filardo TD, Khan MR, Krawczyk N, et al: Comorbidity and clinical factors associated with COVID-19 critical illness and mortality at a large public hospital in New York City in the early phase of the pandemic (March-April 2020). *PLoS One* 2020; 15:e0242760
40. Gayam V, Chobufo MD, Merghani MA, et al: Clinical characteristics and predictors of mortality in African-Americans with COVID-19 from an inner-city community teaching hospital in New York. *J Med Virol* 2021; 93:812–819
41. Chand S, Kapoor S, Orsi D, et al: COVID-19-associated critical illness-report of the first 300 patients admitted to intensive care units at a New York City Medical Center. *J Intensive Care Med* 2020; 35:963–970
42. Turcotte JJ, Meisenberg BR, MacDonald JH, et al: Risk factors for severe illness in hospitalized Covid-19 patients at a regional hospital. *PLoS One* 2020; 15:e0237558
43. Kocayigit H, Özmen Süner K, Tomak Y, et al: Characteristics and outcomes of critically ill patients with Covid-19 in Sakarya, Turkey: A single centre cohort study. *Turk J Med Sci* 2021; 51:440–447
44. Chen Y, Geng Y, Xu X, et al: The features comparison between patients in the ICU and general wards and between patients with different outcomes: A 2020 COVID-19 study. *Ann Palliat Med* 2021; 10:672–680
45. Janz DR, Mackey S, Patel N, et al: Critically ill adults with coronavirus disease 2019 in New Orleans and care with an evidence-based protocol. *Chest* 2021; 159:196–204
46. Mitra AR, Fergusson NA, Lloyd-Smith E, et al: Baseline characteristics and outcomes of patients with COVID-19 admitted to intensive care units in Vancouver, Canada: A case series. *CMAJ* 2020; 192:E694–E701
47. El-Jawahri A, Bohossian HB, Paasche-Orlow MK, et al: Clinical outcomes of patients hospitalized with coronavirus disease 2019 (COVID-19) in Boston. *J Gen Intern Med* 2021; 36:1285–1291
48. Guisado-Vasco P, Valderas-Ortega S, Carralón-González MM, et al: Clinical characteristics and outcomes among hospitalized adults with severe COVID-19 admitted to a tertiary medical center and receiving antiviral, antimalarials, glucocorticoids, or immunomodulation with tocilizumab or cyclosporine: A retrospective observational study (COQUIMA cohort). *EClinicalMedicine* 2020; 28:100591
49. Omrani AS, Almaslamani MA, Daghfal J, et al: The first consecutive 5000 patients with coronavirus disease 2019 from Qatar; a nation-wide cohort study. *BMC Infect Dis* 2020; 20:777
50. Docherty AB, Harrison EM, Green CA, et al: Features of 20 133 UK patients in hospital with Covid-19 using the ISARIC WHO clinical characterisation protocol: Prospective observational cohort study. *BMJ* 2020; 369:m1985
51. Bonnet G, Weizman O, Trimaille A, et al: Critical COVID-19 France Investigators: Characteristics and outcomes of patients hospitalized for COVID-19 in France: The Critical COVID-19 France (CCF) study. *Arch Cardiovasc Dis* 2021; 114:352–363
52. Capone S, Abramyan S, Ross B, et al: Characterization of critically ill COVID-19 patients at a Brooklyn safety-net hospital. *Cureus* 2020; 12:e9809
53. Larsson E, Brattstrom O, Agvald-Ohman C, et al; Karolinska Intensive Care COVID-19 Study Group: Characteristics and outcomes of patients with COVID-19 admitted to ICU in a tertiary hospital in Stockholm, Sweden. *Acta Anaesthesiol Scand* 2021; 65:76–81
54. Cedano J, Fabian Corona E, Gonzalez-Lara M, et al: Characteristics and outcomes of patients with COVID-19 in an intensive care unit of a community hospital; retrospective cohort study. *J Community Hosp Intern Med Perspect* 2021; 11:27–32
55. Temel S, Gündoğan K, Ülger B, et al: Characteristics and outcomes of the patients infected with SARS-CoV-2 admitted to intensive care units: Erciyes university COVID-19 center experience. *Erciyes Med J* 2020; 42:436–440
56. Carrillo-Vega MF, Salinas-Escudero G, Garcia-Pena C, et al: Early estimation of the risk factors for hospitalization and mortality by COVID-19 in Mexico. *PLoS One* 2020; 15:e0238905
57. Israelsen SB, Kristiansen KT, Hindsberger B, et al: Characteristics of patients with COVID-19 pneumonia at Hvidovre Hospital, March-April 2020. *Dan Med J* 2020; 67:A05200313
58. Azoulay E, Fartoukh M, Darmon M, et al: Increased mortality in patients with severe SARS-CoV-2 infection admitted within seven days of disease onset. *Intensive Care Med* 2020; 46:1714–1722
59. Alser O, Mokhtari A, Naar L, et al: Multisystem outcomes and predictors of mortality in critically ill patients with COVID-19: Demographics and disease acuity matter more than comorbidities or treatment modalities. *J Trauma Acute Care Surg* 2021; 90:880–890
60. Boscolo A, Pasin L, Sella N, et al; FERS, for the COVID-19 VENETO ICU Network: Outcomes of COVID-19 patients intubated after failure of non-invasive ventilation: A multicenter observational study. *Sci Rep* 2021; 11:17730
61. Wendel Garcia PD, Fumeaux T, Guerci P, et al; RISC-19-ICU Investigators: Prognostic factors associated with mortality risk and disease progression in 639 critically ill patients with COVID-19 in Europe: Initial report of the international RISC-19-ICU prospective observational cohort. *EClinicalMedicine* 2020; 25:100449
62. Akhter S, Ishaq S, Syed B, et al: Clinical features and in-hospital outcomes in COVID-19 patients: An observational study from Tertiary Care Hospital Karachi, Pakistan. *Pak J Med Health Sci* 2021; 15:1242–1247
63. Ayed M, Borahmah AA, Yazdani A, et al: Assessment of clinical characteristics and mortality-associated factors in COVID-19 critical cases in Kuwait. *Med Princ Pract* 2021; 30:185–192
64. Bastug A, Bodur H, Erdogan S, et al: Clinical and laboratory features of COVID-19: Predictors of severe prognosis. *Int Immunopharmacol* 2020; 88:106950
65. Ñamendys-Silva SA, Alvarado-Ávila PE, Domínguez-Cherit G, et al: Outcomes of patients with COVID-19 in the intensive care unit in Mexico: A multicenter observational study. *Heart Lung* 2021; 50:28–32

66. Peñuelas O, Del Campo-Albendea L, de Aledo ALG, et al: Long-term survival of mechanically ventilated patients with severe COVID-19: An observational cohort study. *Ann Intensive Care* 2021; 11:143
67. Cheng W, Ma XD, Su LX, et al: Retrospective study of critically ill COVID-19 patients with and without extracorporeal membrane oxygenation support in Wuhan, China. *Front Med (Lausanne)* 2021; 8:659793
68. Serrano-Martínez JL, Machado-Casas JF, Redondo-Orts M, et al: Characteristics and results of a series of 59 patients with severe pneumonia due to COVID-19 admitted in the ICU. *Med Intensiva (Engl Ed)* 2020; 44:580–583
69. Kim L, Garg S, O'Halloran A, et al: Risk factors for intensive care unit admission and in-hospital mortality among hospitalized adults identified through the US coronavirus disease 2019 (COVID-19)-associated hospitalization surveillance network (COVID-NET). *Clin Infect Dis* 2021; 72:e206–e214
70. Chew SY, Lee YS, Ghimiray D, et al: Characteristics and outcomes of COVID-19 patients with respiratory failure admitted to a “pandemic ready” intensive care unit - lessons from Singapore. *Ann Acad Med Singap* 2020; 49:434–448
71. Magunia H, Lederer S, Verbuecheln R, et al: Machine learning identifies ICU outcome predictors in a multicenter COVID-19 cohort. *Crit Care* 2021; 25:295
72. Bhargava A, Sharma M, Riederer K, et al: Risk factors for in-hospital mortality from coronavirus disease 2019 infection among black patients-an urban center experience. *Clin Infect Dis* 2021; 73:e4005–e4011
73. Chew MS, Kattainen S, Haase N, et al: A descriptive study of the surge response and outcomes of ICU patients with COVID-19 during first wave in Nordic countries. *Acta Anaesthesiol Scand* 2022; 66:56–64
74. Thomson RJ, Hunter J, Dutton J, et al: Clinical characteristics and outcomes of critically ill patients with COVID-19 admitted to an intensive care unit in London: A prospective observational cohort study. *PLoS One* 2020; 15:e0243710
75. Chen Z, Hu J, Liu L, et al: Clinical characteristics of patients with severe and critical COVID-19 in Wuhan: A single-center, retrospective study. *Infect Dis Ther* 2021; 10:421–438
76. Hernandez-Romieu AC, Adelman MW, Hockstein MA, et al: Timing of intubation and mortality among critically ill coronavirus disease 2019 patients: A single-center cohort study. *Crit Care Med* 2020; 48:e1045–e1053
77. Rieg S, von Cube M, Kalbhenn J, et al; COVID UKF Study Group: COVID-19 in-hospital mortality and mode of death in a dynamic and non-restricted tertiary care model in Germany. *PLoS One* 2020; 15:e0242127
78. Chaudhary S, Benzaquen S, Woo JG, et al: Clinical characteristics, respiratory mechanics, and outcomes in critically ill individuals with COVID-19 infection in an underserved urban population. *Respir Care* 2021; 66:897–908
79. de Souza R, Mhatre S, Qayyumi B, et al: Clinical course and outcome of patients with COVID-19 in Mumbai City: An observational study. *BMJ Open* 2021; 11:e042943
80. Rodríguez A, Ruiz-Botella M, Martín-Loeches I, et al: Deploying unsupervised clustering analysis to derive clinical phenotypes and risk factors associated with mortality risk in 2022 critically ill patients with COVID-19 in Spain. *Crit Care* 2021; 25:63
81. Goshayeshi L, Akbari Rad M, Bergquist R, et al; MUMS Covid-19 Research Team: Demographic and clinical characteristics of severe Covid-19 infections: A cross-sectional study from Mashhad University of Medical Sciences, Iran. *BMC Infect Dis* 2021; 21:656
82. Dosi R, Jain G, Mehta A: Clinical characteristics, comorbidities, and outcome among 365 patients of coronavirus disease 2019 at a Tertiary Care Centre in Central India. *J Assoc Physicians India* 2020; 68:20–23
83. Guglielmetti L, Kontsevaya I, Leoni MC, et al; COVID-Piacenza Group: Severe COVID-19 pneumonia in Piacenza, Italy - a cohort study of the first pandemic wave. *J Infect Public Health* 2021; 14:263–270
84. Brandao Neto RA, Marchini JF, Marino LO, et al: Mortality and other outcomes of patients with coronavirus disease pneumonia admitted to the emergency department: A prospective observational Brazilian study. *PLoS One* 2021; 16:e0244532
85. Haase N, Plovsing R, Christensen S, et al: Characteristics, interventions, and longer term outcomes of COVID-19 ICU patients in Denmark-a nationwide, observational study. *Acta Anaesthesiol Scand* 2021; 65:68–75
86. El Aidaoui K, Haoudar A, Khalis M, et al: Predictors of severity in Covid-19 patients in Casablanca, Morocco. *Cureus* 2020; 12:e10716
87. Yang SS, Lipes J, Dial S, et al: Outcomes and clinical practice in patients with COVID-19 admitted to the intensive care unit in Montréal, Canada: A descriptive analysis. *CMAJ Open* 2020; 8:E788–E795
88. Camporota L, Sanderson B, Dixon A, et al: Outcomes in mechanically ventilated patients with hypoxaemic respiratory failure caused by COVID-19. *Br J Anaesth* 2020; 125:e480–e483
89. Ferrando C, Mellado-Artigas R, Gea A, et al; de la Red de UCI Española para COVID-19: Patient characteristics, clinical course and factors associated to ICU mortality in critically ill patients infected with SARS-CoV-2 in Spain: A prospective, cohort, multicentre study. *Rev Esp Anestesiol Reanim (Engl Ed)* 2020; 67:425–437
90. Ahlstrom B, Frithiof R, Hultstrom M, et al: The Swedish Covid-19 intensive care cohort: Risk factors of ICU admission and ICU mortality. *Acta Anaesthesiol Scand* 2021; 65:525–533
91. Estella Á, Garcia Garmendia JL, de la Fuente C, et al: Predictive factors of six-week mortality in critically ill patients with SARS-CoV-2: A multicenter prospective study. *Med Intensiva (Engl Ed)* 2022; 46:179–191
92. Grasselli G, Greco M, Zanella A, et al: Risk factors associated with mortality among patients with COVID-19 in intensive care units in Lombardy, Italy. *JAMA Intern Med* 2020; 180:1345–1355
93. Gadhya KP, Hansrivijit P, Gangireddy M, et al: Clinical characteristics of hospitalised patients with COVID-19 and the impact on mortality: A single-network, retrospective cohort study from Pennsylvania state. *BMJ Open* 2021; 11:e042549
94. Mekolo D, Bokalli FA, Chi FM, et al: Clinical and epidemiological characteristics and outcomes of patients hospitalized for COVID-19 in Douala, Cameroon. *Pan Afr Med J* 2021; 38:246
95. Zanella A, Florio G, Antonelli M, et al: COVID-19 Italian ICU Network: Time course of risk factors associated with mortality of 1260 critically ill patients with COVID-19 admitted to 24 Italian intensive care units. *Intensive Care Med* 2021; 47:995–1008

96. Rodriguez-Gonzalez CG, Chamorro-de-Vega E, Valerio M, et al: COVID-19 in hospitalised patients in Spain: A cohort study in Madrid. *Int J Antimicrob Agents* 2021; 57:106249
97. Vahedi A, Tabasi F, Monjazebi F, et al: Clinical features and outcomes of ICU patients with COVID-19 infection in Tehran, Iran: A single-centered retrospective cohort study. *Tanaffos* 2020; 19:300–311
98. Roedel K, Jarczak D, Thasler L, et al: Mechanical ventilation and mortality among 223 critically ill patients with coronavirus disease 2019: A multicentric study in Germany. *Aust Crit Care* 2021; 34:167–175
99. Cheng D, Calderwood C, Skyllberg E, et al: Clinical characteristics and outcomes of adult patients admitted with COVID-19 in East London: A retrospective cohort analysis. *BMJ Open Respir Res* 2021; 8:e000813
100. Nasir N, Habib K, Iffat K, et al: Clinical characteristics and outcomes of COVID-19: Experience at a major tertiary care center in Pakistan. *J Infect Dev Ctries* 2021; 15:480–489
101. Nachtigall I, Lenga P, Jóźwiak K, et al: Clinical course and factors associated with outcomes among 1904 patients hospitalized with COVID-19 in Germany: An observational study. *Clin Microbiol Infect* 2020; 26:1663–1669
102. Bhargava A, Szpunar SM, Sharma M, et al: Clinical features and risk factors for in-hospital mortality from COVID-19 infection at a tertiary care medical center, at the onset of the US COVID-19 pandemic. *J Intensive Care Med* 2021; 36:711–718
103. Laake JH, Buanes EA, Smastuen MC, et al: Characteristics, management and survival of ICU patients with coronavirus disease-19 in Norway, March-June 2020. A prospective observational study. *Acta Anaesthesiol Scand* 2021; 65:618–628
104. Ferrando-Vivas P, Doidge J, Thomas K, et al; ICNARC COVID-19 Team: Prognostic factors for 30-day mortality in critically ill patients with coronavirus disease 2019: An observational cohort study. *Crit Care Med* 2021; 49:102–111
105. Campanile A, Verdecchia P, Ravera A, et al: Intensive cardiac care unit admission trends during the COVID-19 outbreak in Italy: A multi-center study. *Intern Emerg Med* 2021; 16:2077–2086
106. Kayina CA, Haritha D, Soni L, et al: Epidemiological & clinical characteristics & early outcome of COVID-19 patients in a tertiary care teaching hospital in India: A preliminary analysis. *Indian J Med Res* 2020; 152:100–104
107. Al Mutair A, Elhazmi A, Alhumaid S, et al: Examining the clinical prognosis of critically ill patients with COVID-19 admitted to intensive care units: A Nationwide Saudi Study. *Medicina (Kaunas)* 2021; 57:878
108. Altunal LN, Aydın M, Özel AS, et al: Experience of a training and research hospital in the first wave of the COVID-19 pandemic; risk factors associated with the need for intensive care. *Klimik Dergisi* 2021; 34:198–202
109. Burrell AJ, Pellegrini B, Salimi F, et al: Outcomes for patients with COVID-19 admitted to Australian intensive care units during the first four months of the pandemic. *Med J Aust* 2021; 214:23–30
110. Galindo JL, Lutz JR, Izquierdo MA, et al: Characteristics and clinical course of adult in patients with SARS-CoV-2 pneumonia at high altitude. *Can Respir J* 2021; 2021:5590879
111. Khan Chachar AZ, Khan K, Khan AA, et al: Clinical and demographic characteristics including comorbidities and their outcomes among patients hospitalized with COVID-19 in four tertiary care hospitals across Lahore. *Cureus* 2021; 13:e12663
112. Roger C, Collange O, Mezzarobba M, et al; AZUREA group: French multicentre observational study on SARS-CoV-2 infections intensive care initial management: The FRENCH CORONA study. *Anaesth Crit Care Pain Med* 2021; 40:100931
113. Donamou J, Toure A, Camara AY, et al: Predictive factors of mortality in patients with COVID-19 in Guinea: Analysis of the first 140 cases admitted to intensive care unit. *Pan Afr Med J* 2021; 38:205
114. Álvarez-Maldonado P, Hernández-Ríos G, Ambríz-Mondragón JC, et al: Characteristics and mortality of Mexican patients with COVID-19 and mechanical ventilation. *Gac Med Mex* 2021; 157:97–101
115. Jalili E, Keramat F, Bashirian S, et al: Demographic and clinical features association with mortality in patients with Covid-19: A cross-sectional study in the West of Iran. *Acta Medica Iranica* 2021; 59:587–594
116. Alkaabi S, Alnuaimi A, Alharbi M, et al: A clinical risk score to predict in-hospital mortality in critically ill patients with COVID-19: A retrospective cohort study. *BMJ Open* 2021; 11:e048770
117. Nassar Y, Mokhtar A, Elhadidy A, et al: Outcomes and risk factors for death in patients with coronavirus disease-2019 (COVID-19) pneumonia admitted to the intensive care units of an Egyptian University Hospital. A retrospective cohort study. *J Infect Public Health* 2021; 14:1381–1388
118. Beatty K, Kavanagh PM: A retrospective cohort study of outcomes in hospitalised COVID-19 patients during the first pandemic wave in Ireland. *Ir J Med Sci* 2022; 191:1973–1983
119. Nachegea JB, Ishoso DK, Otokoye JO, et al: Clinical characteristics and outcomes of patients hospitalized for COVID-19 in Africa: Early insights from the Democratic Republic of the Congo. *Am J Trop Med Hyg* 2020; 103:2419–2428
120. Saha A, Ahsan MM, Quader TU, et al: Characteristics, management and outcomes of critically ill COVID-19 patients admitted to ICU in hospitals in Bangladesh: A retrospective study. *J Prev Med Hyg* 2021; 62:E33–E45
121. de Souza FSH, Hojo-Souza NS, Batista BDO, et al: On the analysis of mortality risk factors for hospitalized COVID-19 patients: A data-driven study using the major Brazilian database. *PLoS One* 2021; 16:e0248580
122. Namendys-Silva SA, Gutiérrez-Villaseñor A, Romero-González JP: Hospital mortality in mechanically ventilated COVID-19 patients in Mexico. *Intensive Care Med* 2020; 46:2086–2088
123. Alghamdi S: Clinical characteristics and treatment outcomes of severe (ICU) COVID-19 patients in Saudi Arabia: A single centre study. *Saudi Pharm J* 2021; 29:1096–1101
124. Al Sulaiman KA, Aljuhani O, Eljaaly K, et al: Clinical features and outcomes of critically ill patients with coronavirus disease 2019 (COVID-19): A multicenter cohort study. *Int J Infect Dis* 2021; 105:180–187
125. Barry M, Althabit N, Akkielah L, et al: Clinical characteristics and outcomes of hospitalized COVID-19 patients in a

- MERS-CoV referral hospital during the peak of the pandemic. *Int J Infect Dis* 2021; 106:43–51
126. Patel BV, Haar S, Handlip R, et al; United Kingdom COVID-ICU National Service Evaluation: Natural history, trajectory, and management of mechanically ventilated COVID-19 patients in the United Kingdom. *Intensive Care Med* 2021; 47:549–565
 127. Cueto-Manzano AM, Espinel-Bermudez MC, Hernandez-Gonzalez SO, et al: Risk factors for mortality of adult patients with COVID-19 hospitalised in an emerging country: A cohort study. *BMJ Open* 2021; 11:e050321
 128. Carboni Bisso I, Huespe I, Lockhart C, et al: Clinical characteristics of critically ill patients with COVID-19. *Medicina (B Aires)* 2021; 81:527–535
 129. Islam MS, Bhowmick DK, Parveen M, et al: Case fatality rate and survival functions of severe COVID-19 patients in intensive care unit of Bangabandhu Sheikh Mujib Medical University in Bangladesh: An observational study. *Anaesth Pain Intensive Care* 2021; 25:443–449
 130. Azad MH, Khorrami F, Jahromi MK, et al: Clinical and epidemiological characteristics of hospitalized COVID-19 patients in Hormozgan, Iran: A retrospective, multicenter study. *Arch Iran Med* 2021; 24:434–444
 131. Bergman J, Ballin M, Nordstrom A, et al: Risk factors for COVID-19 diagnosis, hospitalization, and subsequent all-cause mortality in Sweden: A nationwide study. *Eur J Epidemiol* 2021; 36:287–298
 132. Tyagi A, Tyagi S, Agrawal A, et al: Early warning scores at time of ICU admission to predict mortality in critically ill COVID-19 patients. *Disaster Med Public Health Prep* 2021; 16:2371–2375
 133. Cordova E, Mykietiak A, Sued O, et al; ECCOVID study group: Clinical characteristics and outcomes of hospitalized patients with SARS-CoV-2 infection in a Latin American country: Results from the ECCOVID multicenter prospective study. *PLoS One* 2021; 16:e0258260
 134. Kurtz P, Bastos LSL, Dantas LF, et al: Evolving changes in mortality of 13,301 critically ill adult patients with COVID-19 over 8 months. *Intensive Care Med* 2021; 47:538–548
 135. Estenssoro E, Loudet CI, Rios FG, et al; SATI-COVID-19 Study Group: Clinical characteristics and outcomes of invasively ventilated patients with COVID-19 in Argentina (SATICOVID): A prospective, multicentre cohort study. *Lancet Respir Med* 2021; 9:989–998
 136. Zha L, Sobue T, Takeuchi T, et al: Characteristics and survival of intensive care unit patients with coronavirus disease in Osaka, Japan: A retrospective observational study. *J Clin Med* 2021; 10:2477
 137. Martinot M, Eyriey M, Gravier S, et al; Centre Alsace Study Group: Evolution of baseline characteristics and severe outcomes in COVID-19 inpatients during the first and second waves in Northeastern France. *Infect Dis Now* 2022; 52:35–39
 138. Khamis F, Memish Z, Bahrani MA, et al: Prevalence and predictors of in-hospital mortality of patients hospitalized with COVID-19 infection. *J Infect Public Health* 2021; 14:759–765
 139. Verma R, Nishad RK, Patawa R, et al: Clinical characteristics and outcome of critically ill SARS-CoV-2 patients admitted to intensive care unit of a tertiary care hospital in North India: A retrospective study. *J Clin Diagn Res* 2021; 15:UC05–UC08
 140. Castro MC, Gurzenda S, Macario EM, et al: Characteristics, outcomes and risk factors for mortality of 522 167 patients hospitalised with COVID-19 in Brazil: A retrospective cohort study. *BMJ Open* 2021; 11:e049089
 141. Sharma S, Paneru HR, Shrestha GS, et al: Characteristics and outcome of patients with COVID-19 undergoing invasive mechanical ventilation for respiratory failure in a tertiary level hospital in Nepal. *J Nepal Health Res Counc* 2021; 19:396–401
 142. Elhadi M, Alsoufi A, Abusalama A, et al: Epidemiology, outcomes, and utilization of intensive care unit resources for critically ill COVID-19 patients in Libya: A prospective multicenter cohort study. *PLoS One* 2021; 16:e0251085
 143. El-Hamshari Y, Hamarshi M, Nazzal Z, et al: The outcomes of severe COVID-19 pneumonia managed with supportive care in Palestine: An experience from a developing country. *J Infect Dev Ctries* 2021; 15:1094–1103
 144. Khalid I, Alshukairi AN, Khalid TJ, et al: Characteristics and outcome of tertiary care critically ill COVID-19 patients with multiple comorbidities admitted to the intensive care unit. *Ann Thorac Med* 2022; 17:59–65
 145. Olanipekun T, Abe TA, Effoe VS, et al: Intensive care unit hospitalizations and outcomes in patients with severe COVID-19 during summer and fall surges in Georgia. *World J Crit Care Med* 2021; 10:369–376
 146. Routsis C, Kokkoris S, Siempos I, et al: Fewer intubations but higher mortality among intubated coronavirus disease 2019 patients during the second than the first wave. *Crit Care Explor* 2021; 3:e531
 147. Dennis JM, McGovern AP, Thomas NJ, et al: Trends in 28-day mortality of critical care patients with coronavirus disease 2019 in the United Kingdom: A national cohort study, March 2020 to January 2021. *Crit Care Med* 2021; 49:1895–1900
 148. González J, Benítez ID, de Gonzalo-Calvo D, et al: Impact of time to intubation on mortality and pulmonary sequelae in critically ill patients with COVID-19: A prospective cohort study. *Crit Care* 2022; 26:18
 149. Rosenberger K, Pöschl F, Geschev S, et al: Clinical characterization of hospitalized COVID-19 patients during the second wave of pandemic in the district of Rohrbach, Upper Austria: A single center retrospective study. *Wien Klin Wochenschr* 2021; 133:1248–1254
 150. Mayerhöfer T, Klein SJ, Peer A, et al: Changes in characteristics and outcomes of critically ill COVID-19 patients in Tyrol (Austria) over 1 year. *Wien Klin Wochenschr* 2021; 133:1237–1247
 151. Corrêa TD, Midega TD, Timenetsky KT, et al: Clinical characteristics and outcomes of COVID-19 patients admitted to the intensive care unit during the first year of the pandemic in Brazil: A single center retrospective cohort study. *Einstein (Sao Paulo)* 2021; 19:eAO6739
 152. Karagiannidis C, Hentschker C, Westhoff M, et al: Observational study of changes in utilization and outcomes in mechanical ventilation in COVID-19. *PLoS One* 2022; 17:e0262315
 153. Umeh C, Tuscher L, Ranchithan S, et al: Predictors of COVID-19 mortality in critically ill ICU patients: A multicenter retrospective observational study. *Cureus* 2022; 14:e20952

154. Carbonell R, Urgelés S, Rodríguez A, et al: Mortality comparison between the first and second/third waves among 3,795 critical COVID-19 patients with pneumonia admitted to the ICU: A multicentre retrospective cohort study. *Lancet Reg Health Eur* 2021; 11:100243
155. Taxbro K, Granath A, Sunnergren O, et al: Low mortality rates among critically ill adults with COVID-19 at three non-academic intensive care units in south Sweden. *Acta Anaesthesiol Scand* 2021; 65:1457–1465
156. Doidge JC, Gould DW, Ferrando-Vivas P, et al: Trends in intensive care for patients with COVID-19 in England, Wales, and Northern Ireland. *Am J Respir Crit Care Med* 2021; 203:565–574
157. Kerai S, Singh R, Dutta S, et al: Comparison of clinical characteristics and outcome of critically ill patients admitted to tertiary care intensive care units in India during the peak months of first and second waves of COVID-19 pandemic: A retrospective analysis. *Indian J Crit Care Med* 2021; 25:1349–1356
158. Dongelmans DA, Termorshuizen F, Brinkman S, et al: Characteristics and outcome of COVID-19 patients admitted to the ICU: A nationwide cohort study on the comparison between the first and the consecutive upsurges of the second wave of the COVID-19 pandemic in the Netherlands. *Ann Intensive Care* 2022; 12:5
159. Murthy S, Archambault PM, Atique A, et al; SPRINT-SARI Canada Investigators and the Canadian Critical Care Trials Group: Characteristics and outcomes of patients with COVID-19 admitted to hospital and intensive care in the first phase of the pandemic in Canada: A national cohort study. *CMAJ Open* 2021; 9:E181–E188
160. Hasan SS, Capstick T, Ahmed R, et al: Mortality in COVID-19 patients with acute respiratory distress syndrome and corticosteroids use: A systematic review and meta-analysis. *Expert Rev Respir Med* 2020; 14:1149–1163
161. Armstrong RA, Kane AD, Cook TM: Outcomes from intensive care in patients with COVID-19: A systematic review and meta-analysis of observational studies. *Anaesthesia* 2020; 75:1340–1349
162. Armstrong RA, Kane AD, Kursumovic E, et al: Mortality in patients admitted to intensive care with COVID-19: An updated systematic review and meta-analysis of observational studies. *Anaesthesia* 2021; 76:537–548
163. Potere N, Valeriani E, Candeloro M, et al: Acute complications and mortality in hospitalized patients with coronavirus disease 2019: A systematic review and meta-analysis. *Crit Care* 2020; 24:389
164. Lim ZJ, Subramaniam A, Ponnappa Reddy M, et al: Case fatality rates for patients with COVID-19 requiring invasive mechanical ventilation. A meta-analysis. *Am J Respir Crit Care Med* 2021; 203:54–66
165. Elsayed HH, Hassaballa AS, Ahmed TA, et al: Variation in outcome of invasive mechanical ventilation between different countries for patients with severe COVID-19: A systematic review and meta-analysis. *PLoS One* 2021; 16:e0252760
166. Leazer S, Collen J, Alcover K, et al: Outcomes associated with intensive care and organ support among patients with COVID-19: A systematic review and meta-analysis. *Mil Med* 2022; usac143
167. Mina B, Newton A, Hadda V: Noninvasive ventilation in treatment of respiratory failure-related COVID-19 infection: Review of the literature. *Can Respir J* 2022; 2022:9914081
168. Anger MS, Mullon C, Ficociello LH, et al: Meeting the demand for renal replacement therapy during the COVID-19 pandemic: A manufacturer's perspective. *Kidney360* 2021; 2:350–354
169. Kadri SS, Sun J, Lawandi A, et al: Association between case-load surge and COVID-19 survival in 558 U.S. hospitals, March to August 2020. *Ann Intern Med* 2021; 174:1240–1251
170. Lalloué B, Padget M, Brownwood I, et al: Does size matter? The impact of caseload and expertise concentration on AMI 30-day mortality—a comparison across 10 OECD countries. *Health Policy* 2019; 123:441–448
171. Jeitziner MM, Moser A, Wendel-Garcia PD, et al; RISC-19-ICU Investigators for Switzerland: Critical care staffing ratio and outcome of COVID-19 patients requiring intensive care unit admission during the first pandemic wave: A retrospective analysis across Switzerland from the RISC-19-ICU observational cohort. *Swiss Med Wkly* 2022; 152:w30183